Jasper Therapeutics JSPR Stock
Jasper Therapeutics Price Chart
Jasper Therapeutics JSPR Financial and Trading Overview
| Jasper Therapeutics stock price | 4.89 USD |
| Previous Close | 1.58 USD |
| Open | 1.58 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1000 |
| Day's Range | 1.42 - 1.58 USD |
| 52 Week Range | 0.39 - 3.8 USD |
| Volume | 804.68K USD |
| Avg. Volume | 611.03K USD |
| Market Cap | 162.18M USD |
| Beta (5Y Monthly) | 1.969544 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.89 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.21 USD |
JSPR Valuation Measures
| Enterprise Value | 48.36M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.722222 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.284965 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.942 |
Trading Information
Jasper Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.969544 |
| 52-Week Change | -26.50% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.8 USD |
| 52 Week Low | 0.39 USD |
| 50-Day Moving Average | 1.51 USD |
| 200-Day Moving Average | 1.33 USD |
JSPR Share Statistics
| Avg. Volume (3 month) | 611.03K USD |
| Avg. Daily Volume (10-Days) | 235.7K USD |
| Shares Outstanding | 110.33M |
| Float | 49.47M |
| Short Ratio | 2.63 |
| % Held by Insiders | 7.91% |
| % Held by Institutions | 38.77% |
| Shares Short | 861.53K |
| Short % of Float | 0.88% |
| Short % of Shares Outstanding | 0.77% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -29.84% |
| Return on Equity (ttm) | -51.46% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -51332000 USD |
| Net Income Avi to Common (ttm) | -49738000 USD |
| Diluted EPS (ttm) | -1.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 129.4M USD |
| Total Cash Per Share (mrq) | 1.17 USD |
| Total Debt (mrq) | 3.45M USD |
| Total Debt/Equity (mrq) | 2.75 USD |
| Current Ratio (mrq) | 16.79 |
| Book Value Per Share (mrq) | 1.144 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -41980000 USD |
| Levered Free Cash Flow (ttm) | -25844124 USD |
Profile of Jasper Therapeutics
| Country | United States |
| State | CA |
| City | Redwood City |
| Address | 2200 Bridge Pkwy |
| ZIP | 94065 |
| Phone | 650 549 1400 |
| Website | https://www.jaspertherapeutics.com/ |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 35 |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
Q&A For Jasper Therapeutics Stock
What is a current JSPR stock price?
Jasper Therapeutics JSPR stock price today per share is 4.89 USD.
How to purchase Jasper Therapeutics stock?
You can buy JSPR shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Jasper Therapeutics?
The stock symbol or ticker of Jasper Therapeutics is JSPR.
Which industry does the Jasper Therapeutics company belong to?
The Jasper Therapeutics industry is Biotechnology.
How many shares does Jasper Therapeutics have in circulation?
The max supply of Jasper Therapeutics shares is 15.02M.
What is Jasper Therapeutics Price to Earnings Ratio (PE Ratio)?
Jasper Therapeutics PE Ratio is now.
What was Jasper Therapeutics earnings per share over the trailing 12 months (TTM)?
Jasper Therapeutics EPS is -4.89 USD over the trailing 12 months.
Which sector does the Jasper Therapeutics company belong to?
The Jasper Therapeutics sector is Healthcare.
Jasper Therapeutics JSPR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17166.04 USD — |
+2.74
|
6.86B USD — | 16744.97 USD — | 17174.35 USD — | — - | 6.86B USD — |
| NASDAQ HealthCare IXHC | 930.32 USD — |
+2.05
|
— — | 911.02 USD — | 930.5 USD — | — - | — — |
- {{ link.label }} {{link}}